Evidence map›Paper›PMID 21917913›Full record

ArticleLupus2011

The United States to Africa lupus prevalence gradient revisited.

Gs Gilkeson, Ja James, Dl Kamen, Tj Knackstedt, Dr Maggi, Ak Meyer, Nm Ruth

Open access · greenAbstract readComparative Study
In one paragraph

Article in Lupus, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Frontiers in immunology · 2023
    Article
  8. Review
  9. Review
  10. Global epidemiology of systemic lupus erythematosus.Nature reviews. Rheumatology · 2021
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Gs GilkesonDepartment of Medicine and Pediatrics, Medical University of South Carolina, Charleston, SC 29412, USA. gilkeson@musc.edu
Ja James
Dl Kamen
Tj Knackstedt
Dr Maggi
Ak Meyer
Nm Ruth
Medical University of South Carolina · USFistula Foundation · USOklahoma Medical Research Foundation · US

Funding

SOUTH CAROLINA CLINICAL & TRANSLATIONAL RESEARCH INSTITUTE (SCTR)UL1RR029882 · NCRR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T. · 2009 to 2011
$10.1M
SNP Confirmation and High Throughput Genotyping CoreP30AR053483 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI GUTHRIDGE, JOEL MARVIN · 2007 to 2017
$6.7M
Environmental Determinants of Autoimmunity among African Americans in Coastal SCR21ES017934 · NIEHS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI KAMEN, DIANE L · 2009 to 2012
$1.5M
The Role of Vitamin D in Systemic Lupus ErythematosusK23AR052364 · NIAMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI KAMEN, DIANE L · 2007 to 2011
$647k
NCRR NIH HHS UL1 RR029882NIAMS NIH HHS K23 AR052364NIAMS NIH HHS P30 AR053483NIEHS NIH HHS R21 ES017934
6 · The paper itself

Abstract

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that has a significantly higher prevalence, morbidity and mortality in African Americans compared with Americans of European descent. The pathogenesis of lupus is unclear but appears to be a result of environmental factors interacting with a genetically susceptible host. Despite the high disease load of SLE in African Americans, there is the perception that lupus is relatively rare in Africa. This prevalence gradient suggests that comparative studies of related cohorts from the two continents may provide insight into the genetic/environmental interactions that result in the development of lupus. To define if a lupus gradient exists, we began a study of autoimmunity prevalence utilizing two unique cohorts. The first is the Gullah population of the Sea Islands of South Carolina, who are unique in their low genetic admixture and their known ancestral heritage. The second is the population of young women served by the West Africa Fistula Foundation in Bo, Sierra Leone. Anthropologic studies indicate a direct ancestral link between the Gullah population and Sierra Leoneans. Since it is impossible to perform an epidemiologic study of lupus in Sierra Leone at this time, we assessed the prevalence of lupus serum autoantibodies, serologic evidence of specific infections and levels of serum 25-OH vitamin D in young women in the two cohorts who have no known relatives with lupus. Our results indicate similar prevalence of serum antinuclear antibodies in the two cohorts, though there was a significantly increased prevalence of antiphospholipid and anti-Sm antibodies in the Sierra Leone cohort. Seropositivity to common viral infections was significantly higher in women from Sierra Leone, while serum 25-OH vitamin D levels were markedly lower in the Gullah population. These data suggest that the prevalence of autoimmunity is similar in the two populations, but that there are significant environmental differences that may impact progression to autoimmune disease. Further studies comparing these two cohorts is likely to provide important insight into the impact of environmental factors on development of lupus.

Indexed as

Antibodies, AntinuclearBlack or African AmericanCase-Control StudiesCohort StudiesDisease ProgressionEmigration and ImmigrationEnvironmentFemaleGenetic Predisposition to DiseaseGeorgiaHumansLupus Erythematosus, SystemicPrevalenceSierra LeoneSocial ProblemsSouth Carolina25-hydroxyvitamin DAntibodies, AntinuclearVitamin D

Identifiers

PMID21917913
PMCPMC3535487
OpenAlexW2059487771

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.